MedTrace Logo

Personalized Translational Platform for Biomarker Discovery in Brain Tumors

NCT01240161 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2017-08-29

No results posted yet for this study

Summary

The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.

Conditions

Interventions

DRUG

FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT

Each patient will have 0-3 or more FLT-PET brain scans.

Sponsors & Collaborators

  • Society of Nuclear Medicine and Molecular Imaging

    collaborator UNKNOWN

  • General Electric

    collaborator INDUSTRY

  • Marcelo F. Di Carli, MD, FACC

    lead OTHER

Principal Investigators

  • Marie Kijewski, PhD · Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01240161 on ClinicalTrials.gov